Validating the mode of action of ergosterol peroxide as a selective breast cancer inhibitor
验证过氧化麦角甾醇作为选择性乳腺癌抑制剂的作用方式
基本信息
- 批准号:10411072
- 负责人:
- 金额:$ 11.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-15 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:4T1AddressAffectAfrican AmericanAminoacyl-tRNA hydrolaseAnkyrin RepeatApoptosisBiologicalBiological AssayBiological AvailabilityBiomedical ResearchBiophysicsBreast Cancer CellBreast Cancer ModelBreast Cancer PatientBreast Cancer TreatmentCell DeathCell LineCell modelCellsCellular AssayCessation of lifeChemicalsCholesterolCholesterol HomeostasisClinicClinical ResearchClustered Regularly Interspaced Short Palindromic RepeatsComplexCytosolDataDependenceDevelopmentDiagnosisDiseaseDoseDoxycyclineDrug toxicityERBB2 geneEarly DiagnosisEnvironmentEnzymesErgosterolExcisionExtravasationFemaleFutureGenesGoalsHispanic AmericansHomeostasisImpairmentIn complete remissionKnowledgeLeadLigationMCF10A cellsMalignant NeoplasmsMembraneMitochondriaMitochondrial ProteinsModalityModelingMusNatural ProductsNormal CellNormal tissue morphologyOxidation-ReductionOxidative StressPathway interactionsPatient-derived xenograft models of breast cancerPatientsPeroxidesPharmacologyPrognosisPropertyProtacProteinsPuerto RicoRecurrenceResearchResistanceSafetyScientistSteroidsSterolsStructureStudentsSubstrate SpecificitySurvival RateSystemTestingTherapeuticTherapeutic AgentsToxic effectTumor VolumeUbiquitinUbiquitinationUnited StatesWomanXenograft procedureZinc Fingersaggressive breast canceranti-cancer therapeuticantiproliferative agentsbasecancer cellcancer subtypeschemotherapyclinically relevantefficacy testingfungusimprovedin vivoin vivo Modelinhibitormalignant breast neoplasmmisfolded proteinmitochondrial dysfunctionmortalitymouse modelmulticatalytic endopeptidase complexneoplastic cellnovelpharmacokinetics and pharmacodynamicspre-clinicalprotein aggregationprotein complexpublic health relevancestemstudent participationtargeted treatmenttriple-negative invasive breast carcinomatumor progressionunderrepresented minority studentuptakevalosin-containing proteinwomen of color
项目摘要
PROJECT SUMMARY
Triple Negative Breast Cancer (TNBC) is an aggressive and lethal breast cancer subtype more commonly
diagnosed on younger (<40y) women of color (Hispanics and African American), who are more likely to have
disease recurrence and who have an overall shorter survival. Furthermore, additional limitations (i.e. drug
toxicity, and therapy resistance) persist in the clinic for TNBC patients. Thus, a critical need exists to discover
more desirable targeted therapeutic modalities that selectively target TNBC tumor cells while leaving normal
cells unaffected, enhancing a complete response and reducing TNBC-associated mortality rates. Accordingly,
our goal is to reduce BC mortality by identifying unique vulnerabilities of TNBC that can be exploited through the
development of selective therapeutic agents. We recently identified the natural product ergosterol peroxide a
steroidal compound found in fungi, as a potent antiproliferative agent against TNBC cell models with little to no
effect on noncancerous cells. We demonstrated that EP is more potent towards TNBC than HER2-positive
models. EP induces ROS and apoptosis in TNBC cells and reduces tumor volume in TNBC models in vivo.
However, EP’s mode of action (MOA) remains to be defined. Extended periods of oxidative stress in the
mitochondria lead to accumulation of damaged proteins, which are normally removed by ubiquitination via the
VCP/ANKZF1 pathway. We have synthesized EP in gram scale and show that EP accumulates in the cytosol
and affects VCP and ANKZF1 interactions, raising the possibility that the VCP/ANKZF1 complex is targeted
during its assembly prior to arriving to the mitochondria. Thus, taking advantage of TNBC’s dependency on sterol
uptake, removal of misfolded proteins and altered redox homeostasis, we propose that EP serves as a
VCP/ANKZF1 complex protein-protein inhibitor (PPI). We hypothesize that EP targets the VCP/ANKZF1
complex, impairing the ability of cancer cells to clear damaged proteins and causing mitochondria dysfunction to
induce TNBC cell death. To test the hypothesis we will identify the mechanism by which EP targets the
VCP/ANKZF1 complex in TNBC models using biophysical assays and synthesized EP-probes (Aim 1). The
results from this Aim will validate that targeting VCP/ANKZF1 complex induces increases misfolded and
aggregated proteins, which lead to cancer cell death. We will determine the efficacy of EP using syngeneic
models injected with doxycycline inducible ANKZF1 silenced cells, and in TNBC PDXs. EP safety and bio-
availability will also be determined and studied by MTD and PK/PD (Aim 2). The result of this aim will provide
data needed for the next step towards the translational development of EP. Student participation in this
hypothesis-driven research will improve the pipeline for URM students in biomedical research and lead to
improved BC treatment.
项目概要
三阴性乳腺癌 (TNBC) 是一种更常见的侵袭性和致命性乳腺癌亚型
诊断为年轻(<40 岁)有色人种女性(西班牙裔和非裔美国人),她们更有可能患有
疾病复发和总体生存期较短的人。此外,还有其他限制(即药物
对于 TNBC 患者来说,临床上仍然存在这种情况。因此,迫切需要发现
更理想的靶向治疗方式,选择性靶向 TNBC 肿瘤细胞,同时保留正常细胞
细胞不受影响,增强完全反应并降低 TNBC 相关死亡率。因此,
我们的目标是通过识别 TNBC 的独特漏洞来降低 BC 死亡率,这些漏洞可以通过
开发选择性治疗剂。我们最近发现了天然产物过氧化麦角甾醇a
在真菌中发现的类固醇化合物,作为针对 TNBC 细胞模型的有效抗增殖剂,几乎没有作用
对非癌细胞的影响。我们证明 EP 对 TNBC 比 HER2 阳性更有效
模型。 EP 可诱导 TNBC 细胞中的 ROS 和细胞凋亡,并减少体内 TNBC 模型中的肿瘤体积。
然而,EP 的作用模式 (MOA) 仍有待定义。长时间的氧化应激
线粒体导致受损蛋白质的积累,这些蛋白质通常通过泛素化通过
VCP/ANKZF1 通路。我们合成了克级的 EP,并表明 EP 在细胞质中积累
并影响 VCP 和 ANKZF1 相互作用,增加了 VCP/ANKZF1 复合物被靶向的可能性
在到达线粒体之前的组装过程中。因此,利用 TNBC 对甾醇的依赖
摄取、去除错误折叠的蛋白质和改变氧化还原稳态,我们建议 EP 作为
VCP/ANKZF1 复合蛋白-蛋白抑制剂 (PPI)。我们假设 EP 针对 VCP/ANKZF1
复杂,损害癌细胞清除受损蛋白质的能力并导致线粒体功能障碍
诱导TNBC细胞死亡。为了检验这个假设,我们将确定 EP 靶向的机制
使用生物物理测定和合成的 EP 探针在 TNBC 模型中形成 VCP/ANKZF1 复合物(目标 1)。这
该目的的结果将验证靶向 VCP/ANKZF1 复合物会诱导错误折叠和
聚集的蛋白质,导致癌细胞死亡。我们将使用同基因确定 EP 的功效
注射强力霉素诱导的 ANKZF1 沉默细胞的模型以及 TNBC PDX。 EP安全和生物
可用性也将通过 MTD 和 PK/PD 来确定和研究(目标 2)。这一目标的结果将提供
下一步 EP 转化开发所需的数据。学生参与本次活动
假设驱动的研究将改善 URM 学生在生物医学研究方面的渠道,并导致
改善 BC 治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michelle M Martínez其他文献
Pharmacological zinc and phytase supplementation enhance metallothionein mRNA abundance and protein concentration in newly weaned pigs.
药理学锌和植酸酶补充剂可增强刚断奶仔猪的金属硫蛋白 mRNA 丰度和蛋白质浓度。
- DOI:
- 发表时间:
2004 - 期刊:
- 影响因子:0
- 作者:
Michelle M Martínez;G. Hill;J. Link;N. Raney;R. Tempelman;C. Ernst - 通讯作者:
C. Ernst
Michelle M Martínez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michelle M Martínez', 18)}}的其他基金
Validating the mode of action of ergosterol peroxide as a selective breast cancer inhibitor
验证过氧化麦角甾醇作为选择性乳腺癌抑制剂的作用方式
- 批准号:
10610422 - 财政年份:2022
- 资助金额:
$ 11.7万 - 项目类别:
INVESTIGATION OF REISHI AS A NATURAL THERAPEUTIC FOR INFLAMMATORY BREAST CANCER
灵芝作为炎性乳腺癌天然疗法的研究
- 批准号:
8357105 - 财政年份:2011
- 资助金额:
$ 11.7万 - 项目类别:
INVESTIGATION OF REISHI AS A NATURAL THERAPEUTIC FOR INFLAMMATORY BREAST CANCER
灵芝作为炎性乳腺癌天然疗法的研究
- 批准号:
8166209 - 财政年份:2010
- 资助金额:
$ 11.7万 - 项目类别:
INVESTIGATION OF REISHI AS A NATURAL THERAPEUTIC FOR INFLAMMATORY BREAST CANCER
灵芝作为炎性乳腺癌天然疗法的研究
- 批准号:
8573333 - 财政年份:1997
- 资助金额:
$ 11.7万 - 项目类别:
INVESTIGATION OF REISHI AS A NATURAL THERAPEUTIC FOR INFLAMMATORY BREAST CANCER
灵芝作为炎性乳腺癌天然疗法的研究
- 批准号:
8573407 - 财政年份:
- 资助金额:
$ 11.7万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 11.7万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 11.7万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 11.7万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 11.7万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 11.7万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 11.7万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 11.7万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 11.7万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 11.7万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 11.7万 - 项目类别:
Research Grant